netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
01.05.03  Expand sub section  Drugs affecting the immune response
Anti-MAP (mycobacterium avium paratuberculosis) therapy (clarithromycin, rifabutin and clofazimine)
View adult BNF View SPC online
Formulary
Red

Specialist gastroenterology use only

Follow local guidelines for use at GSTT Patient Information Leaflet available on GTi (GSTT intranet)

Last line option for Crohn's disease patients who have not responded to/have been intolerant of or have a contraindication to treatment options and strategies for Crohn’s disease outlined within the SEL IBD Pathways (including immunosuppressants and biologics) and do not wish to have surgery.

Regimen:

  • Clarithromycin 250 mg each morning and 500 mg at night
  • Rifabutin 150 mg daily for 1 week, then 150 mg twice daily. If >50kg the dose may be increased to 450mg total daily dose
  • Clofazimine 100 mg daily (unlicensed product) The maximum treatment duration is 2 years
 
Link  SE London APC recommendation: Clofazimine in combination with clarithromycin and rifabutin as anti-MAP (Mycobacterium avium subspecies paprtuberculosis) therapy for the treatment of Crohn’s disease in adults
   
Cytotoxic Drug Azathioprine tablets (inflammatory bowel disease - off-label)
View adult BNF View SPC online
Formulary
Amber 3

Approved off-label indication:

Resistant or frequently relapsing inflammatory bowel disease Dose: 2 mg/kg daily For shared care arrangements, see guideline below

 
Link  SE London APC Shared Care Agreement: Azathioprine and Mercaptupurine in Inflammatory Bowel Disease
   
Ciclosporin injection (ulcerative colitis - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Severe acute ulcerative colitis refractory to corticosteroid treatment. Dose: 2 mg/kg over 24hours and dose adjusted according to blood-ciclosporin concentration and response

 
   
Cytotoxic Drug Mercaptopurine tabs (IBD - off-label)
View adult BNF View SPC online
Formulary
Amber 3
Approved off-label indications:
  • Severe acute inflammatory bowel disease (IBD)
  • Maintenance of remission of IBD For shared care arrangements, see guideline below 
  • Link  SE London APC Shared Care Agreement: Azathioprine and Mercaptupurine in Inflammatory Bowel Disease
       
    Cytotoxic Drug Methotrexate tablets (Crohn’s disease - off-label)
    View adult BNF View SPC online
    Formulary

    Approved off-label indication:

    Crohn’s disease Dose 15-25 mg weekly

     
       
    Tacrolimus (Adoport®) (IBD - off-label)
    (Prescribe by brand)
    View adult BNF View SPC online
    Formulary
    Red

    Approved off-label indication:

    Refractory Crohn’s disease or ulcerative colitis, in patients who have failed or are contraindicated to all other conventional immunosuppressant and biological treatments.

     
       
    Tioguanine tabs (IBD - off-label)
    View adult BNF View SPC online
    Formulary
    Red

    Approved off-label indication:

    3rd line oral immunosuppressive agent for maintaining remission in adult patients with Crohn’s disease and ulcerative colitis

    • For use in patients who are intolerant or unresponsive to both azathioprine and mercaptopurine
    • Hospital prescribing and supply only
    • Dose: 20 mg to 40 mg daily
     
    Link  SE London APC recommendation: Tioguanine for the treatment of adults with inflammatory bowel disease
       
    Tacrolimus ointment (perianal Crohn’s disease - off-label)
    View adult BNF View SPC online
    Formulary

    Approved off-label indication:

    Ulcerating perianal Crohn’s disease and pyoderma gangrenosum as a last-line option if all other therapies and surgery have failed or are unsuitable

     
       
    01.05.03  Expand sub section  Cytokine inhibitors
    Adalimumab injection (IBD)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Approved as per NICE technology appraisal guidance  
    Link  NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
    Link  NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
       
    Infliximab injection (IBD)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Approved as per NICE technology appraisal guidance

    Biosimilar products available, to be prescribed by brand name. Contact pharmacy department for advice on brand for routine prescribing if unsure

     
    Link  NICE TA163 Infliximab for acute exacerbations of ulcerative colitis
    Link  NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
    Link  NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
    Link  SE London APC position statement: Biosimilar infliximab
       
    Golimumab injection (ulcerative colitis)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Approved as per NICE technology appraisal guidance Approved off-label use: Increased dose of 100mg every 4 weeks in those <80kg who have had a partial response, or secondary loss of response to the 50mg dose 
    Link  NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
       
    Infliximab injection (cancer immunotherapy related colitis - off-label)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Approved off-label indication:

    Treatment of cancer immunotherapy (ipilimumab, nivolumab and pembrolizumab) related corticosteroid refractory colitis

    • Category B* form required
    • Restricted to use in in patients where conservative measures (e.g. loperamide, fluid replacement, withholding immunotherapy treatment) and high dose intravenous corticosteroids have failed
    • Approved for a maximum of 2 doses at 5mg/kg
     
       
    Ustekinumab injection (Crohn's disease)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Approved as per NICE technology appraisal guidance 
    Link  NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
       
    01.05.03  Expand sub section  Vedolizumab
    Vedolizumab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
     
    Link  NICE TA342 Vedolizumab for treating moderately to severely active ulcerative colitis
    Link  NICE TA352 Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
       
     ....
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    SMC
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

    Amber 1

    Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

    Amber 2

    Specialist initiation followed by maintenance prescribing in primary care  

    Amber 3

    Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

    Green

    Specialist and non-specialist initiation  

    Grey

    Not recommended for prescribing  

    netFormulary